This week has seen Generics Bulletin publish its annual Top 50 ranking for 2024 of the leading companies across the generics and biosimilars industry.
Across three separate articles, we showed how the global top ten companies are seeing change, despite remaining a stable leading group; we looked at the ups and downs of mid-table players; and completed our ranking with a look at how some firms have altogether dropped out of the bottom of our table this year.
Now, we compile all of the data from these three articles in one place for ease of reference.
We also bring you the data from which the ranking was calculated, based on publicly-available reported information from all 50 companies as well as additional information provided directly to Generics Bulletin where relevant.
And this year, for the first time, our full ranking allows you to compare the current Top 50 with those of previous years, by using the drop-down menu on the top left.
You can also use the sidebar to navigate to our three individual articles, offering additional commentary on our three tables covering positions 1-10, 11-30 and 31-50.
[T#:2E3647C3-09BB-4507-BE8B-80F4F546738E]
Our top 50 ranking compiles sales data for 2023 – or the closest available reported year – for those firms for which generics and/or biosimilars is a major part of their business. This excludes companies predominantly focused on active pharmaceutical ingredients, some of which report sales totals that would otherwise be sufficient to be featured in the list.
It also means that originators with significant generics or biosimilars interests but which do not split out their totals as separate segments – such as Amgen and Pfizer – are not included, even though the size of these businesses would otherwise be enough to put them in contention.
We also do not include companies that do not disclose detailed sales information, meaning that privately-held players such as Apotex, Polpharma, Alvogen and Zentiva are absent from our rankings.
Publicly reported sales data for 2023, or the closest available financial year, has been allocated to our categories – the key category covering generics, biosimilars, APIs and OTC; a separate category covering branded prescription sales; and a final category for sales that do not fall into either of these categories – and, where not reported in US dollars, has been converted at representative exchange rates for 2023.
